Anthera Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTH research report →
Companywww.anthera.com
Anthera Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
- CEO
- Paul F. Truex
- IPO
- 2010
- Employees
- 21
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $2.62K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -485.59%
- ROIC
- 3509.83%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-16,935,000 · 68.41%
- EPS
- $-1.65 · 84.10%
- Op Income
- $-36,432,000
- FCF YoY
- 25.73%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -123.12
- Avg Volume
- 2.26K
Get TickerSpark's AI analysis on ANTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 18 | THOMPSON JOHN CRAIG | other | 1,847,074 |
| Jan 5, 18 | SHANAHAN WILLIAM R JR | other | 567,876 |
| Jan 5, 18 | TRUEX PAUL F | other | 84,705 |
| Jan 5, 18 | Thompson David E. | other | 84,705 |
| Jan 5, 18 | Sager Philip | other | 84,705 |
| Jan 5, 18 | Mueller Brian | other | 84,705 |
| Jan 5, 18 | Furse Brent | other | 84,705 |
| Jan 5, 18 | HENNEY CHRISTOPHER S | other | 84,705 |
| Sep 20, 17 | THOMPSON JOHN CRAIG | buy | 8,550 |
| Sep 7, 17 | TRUEX PAUL F | buy | 5,000 |
Our ANTH Coverage
We haven't published any research on ANTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANTH Report →